Arix Bioscience plc notes positive clinical study announcements from Autolus Limited

Arix Bioscience plc notes positive clinical study announcements from Autolus Limited

LONDON, 18 September 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting medical innovation, is pleased to note two positive press releases today by Autolus Limited ("Autolus"), an Arix Bioscience Group Business, announcing clinical progress across its portfolio.

The first release today from Autolus announced the completion of the first-dose cohort of its Phase I/II study of AUTO2, its novel, dual-targeted Chimeric Antigen Receptor (CAR) in patients with relapsed/refractory melanoma.

Autolus' AUTO2 is a CAR-T cell therapy that targets both B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). AUTO2 re-programmes the patient's own T cells to minimize the risk of cancer cells escaping treatment. AUTO2 is the first example of Autolus' approach to unlocking the curative potential of CAR-T cell therapies.

The second release today from Autolus announced initiation of both the AMELIA and ALEXANDER Phase I/II studies for AUTO3, its novel, dual-targeting, AUTO3 CAR T cell therapy, for paediatric Acute Lymphocytic Leukaemia (ALL) and adult Diffuse Large B-Cell Lymphoma (DLBCL).

Autolus' AUTO3 seeks to overcome two limitations of current therapies by introducing dual targeting CARs and addressing checkpoint mediated inhibition.

Joe Anderson, Chief Executive Officer of Arix Bioscience, commented: "Cell therapy has the potential to advance cancer treatment substantially and the announcements today from Autolus are an important step in this campaign.  CAR-T is a proven, new approach to cancer treatment and Autolus has the science and the team to substantially advance this field, with a differentiated technology.   We are privileged to work with the company and our co-investors to help advance these goals."

For more information, please contact:

Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052

Matthew Cole, Communications Director
+44 (0) 20 7290 1065

Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
[email protected]

About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

About Autolus Limited

Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer.  Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.  For further information please visit the Company's website at: www.autolus.com